Real-World Data from Italy: Luspatercept Shows Promise in Transfusion-Dependent Beta-Thalassemia
Mostafa Faisal, associate professor of Adult Hematology and BMT, recently shared a post on use of Luspatercept on X:
”Luspatercept for Transfusion-Dependent Beta-Thalassemia: Real-World Experience in a Large Cohort of Patients From Italy – The American Journal of Hematology.”
Read the full article here.
Following the approval of the drug in the U.S. and Europe—based on the findings of the randomized, placebo-controlled phase III BELIEVE trial—there remained a need to generate robust real-world evidence on its effectiveness, safety, and tolerability in routine clinical settings.
To address this, the impact of luspatercept treatment in a cohort of 231 individuals with TDT was assessed.
Published in the American Journal of Hematology, this new study presents one of the largest real-world cohorts examining the use of the drug in patients with transfusion-dependent beta-thalassemia (TDT) across Italy.
To learn more on new scientific advances in hematology, read Hemostasis Today.
-
Jul 5, 2026, 22:51Shahzaib Akram: What Are We Actually Seeing When a Sickling Test Goes Positive?
-
Jul 5, 2026, 21:474 Tips for Exercising with A Bleeding Disorder – Haemophilia Foundation Australia
-
Jul 5, 2026, 21:06Heghine Khachatryan: Toward Personalized Management of Glanzmann Thrombasthenia
-
Jul 5, 2026, 21:06Priyanka Kumari: IV Fluids and Isotonic Solution
-
Jul 5, 2026, 21:05Ahmed Rizq: Would You Thrombolyse a Stable Patient?
-
Jul 5, 2026, 21:03Emmanuel Obeng Ofori: Diagnosing Anaemia – Why Treating the Root Cause Matters More Than Simply Raising the Haemoglobin
-
Jul 5, 2026, 21:02Mohit Koladia: The Pharmacist’s Role in Stroke Prevention for Atrial Fibrillation
-
Jul 5, 2026, 20:22J. Meireles-Brandao: Exploring the Approach to Thrombophillias
-
Jul 5, 2026, 20:13Kavya Keerthana: The Platelet Count Everyone Calls ‘Reactive’ Until It Isn’t